FLT3 and acute myeloid leukemia: In this way, PRMT5, CDK9 and DHODH were identified as synthetic lethal partners of the FLT3 inhibitor gilteritinib by inhibiting the switch to oxidative phosphorylation in FLT3-ITD AML [31].